Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › PCVX
SILVERARC CAPITAL MANAGEMENT, LLC position in PCVX
VAXCYTE INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 125,080 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$7.1M, representing 0.91% of its reported portfolio and ranking #30 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed PCVX holdings in 9 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's PCVX position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in PCVX in Q2 2024 at 2,500 shares (US$189K). The position peaked in Q3 2025 at 314,339 shares, worth US$11.3M. Across 9 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 125,080 shares valued at US$7.1M — a reduction of -19,920 shares quarter over quarter.. Notable position changes include a 2320% increase in Q3 2024 (shares fell 28% over the following quarter), a 33% trim in Q4 2024 (shares fell 54% over the following quarter), a 53% trim in Q4 2025 (shares rose 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 2.50K | $188.78K | New |
| Q3 2024 | 60.50K | $6.91M | Add |
| Q4 2024 | 40.79K | $3.34M | Reduce |
| Q2 2025 | 287.80K | $9.36M | New |
| Q3 2025 | 314.34K | $11.32M | Add |
| Q4 2025 | 148.79K | $6.87M | Reduce |
| Q1 2026 | 144.98K | $8.42M | Reduce |
| Q2 2026 | 145.00K | $8.43M | Hold |
| Q3 2026 | 125.08K | $7.12M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 33 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M sh · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M sh · $249.96M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 3.28M sh · $186.60M · Q3 2026
- Kynam Capital Management, LP 2.92M sh · $169.88M · Q2 2026
- Caligan Partners LP 2.19M sh · $127.23M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M sh · $123.69M · Q2 2026
- Bellevue Group AG 1.97M sh · $114.63M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M sh · $93.78M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held PCVX?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed PCVX holdings in 9 of the last 10 reported quarters, going back to Q2 2024.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in PCVX?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 125.08K shares of PCVX (VAXCYTE INC), valued at $7.12M, representing 0.91% of its reported portfolio and ranking #30.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling PCVX?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in PCVX. The position peaked in Q3 2025 at 314.34K shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.